Salesforce (CRM) posted a record first quarter after the bell on May 27, 2026. EPS beat by nearly 24%. Revenue came in ahead of every major estimate. And the stock fell anyway. That reaction tells you the full story of where this name sits right now.
CRM's Q1 FY2027 numbers in detail
Salesforce delivered non-GAAP EPS of $3.88 against a consensus of $3.12, a beat of 24%. Revenue reached $11.13 billion, up 13% year over year, clearing the $11.05 billion Wall Street expected.
The Agentforce AI platform was the headline driver. Agentforce ARR grew 205% year over year to $1.2 billion, and the combined Agentforce and Data 360 ARR reached nearly $3.4 billion. The company processed 3.8 billion Agentic Work Units to date, up 111% quarter over quarter.
Margins hit record highs. Non-GAAP operating margin reached 34.8%, up 250 basis points. GAAP operating margin came in at 21.1%, up 130 basis points.
The weakness was Q2 guidance. Salesforce guided Q2 revenue of $11.27 to $11.35 billion, representing roughly 10% constant-currency growth. Operating cash flow guidance was updated to reflect a 4 to 5% headwind from debt issued to fund a $25 billion accelerated share repurchase. The street wanted more. Shares fell roughly 3% in post-market trading.
What the Stoxcraft scores say about CRM right now
The score split on Salesforce is one of the sharpest in the entire Stoxcraft database. Two scores are pulling in opposite directions, and that tension is exactly what tonight's earnings either resolves or extends.
Health score: a fundamentally sound business
Salesforce's Health Score of 7.0/10 reflects genuine financial strength. It ranks inside the top 30% of all application software companies in the Stoxcraft universe on fundamental quality. Free cash flow for fiscal year 2026 reached $14.4 billion, up 16% year over year, while operating cash flow came in at $15.0 billion. That kind of generation is what underpins the health reading.
The Informatica acquisition brought incremental revenue complexity, but the underlying cash engine remained intact. The score isn't at the very top of the sector because growth has decelerated from prior years and integration costs add near-term drag. The fundamentals have not broken down.
Performance score: the hardest number on the card
A Performance Score of 0.0/10 is not a rounding error. It reflects a stock that has underperformed essentially every benchmark across every major time horizon in the Stoxcraft universe. As of Wednesday's close, Salesforce shares were down 33% year to date in 2026, while the S&P 500 had gained roughly 10%. The multi-year relative performance picture is equally damaged.
The score sits at the bottom 1% of the Stoxcraft universe. The business generates billions in free cash flow. The stock has been crushed regardless. That is the divergence this earnings report was meant to start closing.
CRM's trend and entry signal after the Q1 reaction
Short-term momentum on CRM is firmly negative. The stock's technical setup reflects an established downtrend, with every major short-term signal pointing downward. The RSI has been depressed for months. The distance from the 52-week high remains substantial. A Q2 guidance miss extending into post-market trading adds another layer of near-term pressure.
The entry signal sits at Hold. Analyst consensus remains broadly constructive on the long-term thesis, but the RSI setup and stock price proximity to multi-year lows do not create a clean technical entry window. The current setup rewards patience over urgency. Shares had bottomed near $164 in mid-May before staging a partial recovery to just below $180 heading into the print. Post-market pressure suggests that recovery may be tested again.
CRM vs. the application software sector
The application software sector in the Stoxcraft universe carries a mixed profile right now. Fundamentals are broadly solid. Performance scores are diverging sharply between AI-native beneficiaries and legacy software names facing pricing and narrative pressure. Salesforce sits squarely in the second group.
CRM's Health Score of 7.0/10 is above the sector median. Its Performance Score of 0.0/10 is among the very worst in the sector. That combination puts it in a specific archetype: a fundamentally sound business whose stock has experienced severe momentum loss and elevated volatility relative to the broader tech landscape.
CRM fits the fallen angel pattern
Salesforce currently fits the Fallen Angel profile in Stoxcraft's scoring framework. A strong Health Score against severe performance underperformance typically signals one of two outcomes: the gap closes via a re-rating, or the fundamentals eventually erode to match the stock. Tonight's guidance miss keeps the re-rating thesis on hold.
The AI narrative is genuinely large. Agentforce at $1.2 billion ARR growing 205% is not a placeholder product. But the market is asking whether that growth rate can replace the deceleration in legacy CRM products. Tonight's Q2 guidance, which implies roughly 10% constant-currency growth, did not answer that question convincingly.
What CRM's Q2 results need to prove
The earnings setup going into Q2 is exactly what the score anomaly predicted. A business with world-class cash flow power and a Performance Score at zero means something has to move. Either the stock recovers or the Health Score begins to weaken.
The next catalyst is Q2, due late August. The market needs Agentforce net new ARR to accelerate, organic revenue growth to reaccelerate in the second half as management guided, and Q2 revenue to land at or above $11.35 billion. If those three conditions are met together, the current 2-star overall rating has a credible path toward 3 stars and a potential re-rating of the technical picture. Until then, the Hold signal stands.
